

Boston Scientific Launches Promus PREMIER™ Everolimus-Eluting Platinum Chromium Coronary Stent System In Japan

NATICK, Mass., May 1, 2014 [/PRNewswire/](#) -- Continuing to advance leading drug-eluting stent (DES) technology, Boston Scientific Corporation (NYSE: BSX) has launched the Promus PREMIER™ Everolimus-Eluting Platinum Chromium Coronary Stent System in Japan. This advanced DES system recently received Japan Ministry of Health, Labor and Welfare (MHLW) approval.

"It is my great pleasure to be able to provide the [Promus PREMIER™ Stent System](#) to physicians and patients in Japan," said Yusuke Naiki, president and representative director for Boston Scientific Japan K.K. "This innovative stent enhances our portfolio of coronary intervention products, and we believe it will strengthen our position in Japan's DES market."

Coronary artery disease is a narrowing of blood vessels that supply blood and oxygen to the heart. Patients with coronary artery disease may experience pain, shortness of breath and fatigue. They may also be at risk for a heart attack. One treatment option is the placement of a stent in the artery to help keep it open and allow the blood to flow more freely.

The Promus PREMIER Stent System was developed with extensive input from interventional cardiologists and is designed to provide best-in-class acute performance and clinical outcomes. It features unparalleled visibility and low recoil, plus exceptional radial strength and fracture resistance. An enhanced low-profile delivery system is designed to facilitate precise stent delivery across challenging lesions.

"The Promus PREMIER Stent System reflects our commitment to DES technology and to providing interventional cardiologists with the most complete portfolio of clinical solutions," said Kevin Ballinger, president, Interventional Cardiology, Boston Scientific. "Japan is an important interventional cardiology market, and we believe the launch and success of this stent system in Japan will enhance Boston Scientific's overall growth strategy in the DES market."

The Promus PREMIER Stent System received CE Mark and FDA approvals in February and November of 2013, respectively.

About Boston Scientific

Boston Scientific transforms lives through innovative medical solutions that improve the health of patients around the world. As a global medical technology leader for more than 30 years, we advance science for life by providing a broad range of high performance solutions that address unmet patient needs and reduce the cost of healthcare. For more information, visit www.bostonscientific.com and connect on [Twitter](#) and [Facebook](#).

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "intend" and similar words. These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things, statements regarding our business plans, markets for our products, new product launches and launch cadence, regulatory approvals, product performance and impact, and competitive offerings. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.

Factors that may cause such differences include, among other things: future economic, competitive, reimbursement and regulatory conditions; new product introductions; demographic trends; intellectual property; litigation; financial market conditions; and future business decisions made by us and our competitors. All of these factors are difficult or impossible to predict accurately and many of them are beyond our control. For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A – *Risk Factors* in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A – *Risk Factors* in Quarterly Reports on Form 10-Q we have filed or will file hereafter. We disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, conditions or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements. This cautionary statement is applicable to all forward-looking statements contained in this document.

CONTACTS:

Media: Ryan Davenport
Global Media Relations
Boston Scientific Corporation
763-494-2664 (office)
media@bsci.com

Kenichi Kitawaki
Japan Corporate Communications
Boston Scientific Japan
81-3-6853-6946 (office)
Kenichi.Kitawaki@bsci.com

Susie Lisa, CFA
Investor Relations
Boston Scientific Corporation
508-652-5345 (office)
investor_relations@bsci.com

SOURCE Boston Scientific

<https://news.bostonscientific.com/2014-05-01-Boston-Scientific-Launches-Promus-PREMIER-Everolimus-Eluting-Platinum-Chromium-Coronary-Stent-System-In-Japan>